Cart
sales@molnova.com
GSK-3β inhibitor 1 (b)
CAS No. 3367-88-2
GSK-3β inhibitor 1 (b)( —— )
Catalog No. M24282 CAS No. 3367-88-2
GSK-3β inhibitor 1 is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 57 | In Stock |
|
| 2MG | 30 | In Stock |
|
| 5MG | 51 | In Stock |
|
| 10MG | 86 | In Stock |
|
| 25MG | 157 | In Stock |
|
| 50MG | 230 | In Stock |
|
| 100MG | 328 | In Stock |
|
| 200MG | 446 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK-3β inhibitor 1 (b)
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK-3β inhibitor 1 is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy.
-
DescriptionGSK-3β inhibitor 1 is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetGSK-3
-
RecptorGSK-3β
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3367-88-2
-
Formula Weight222.24
-
Molecular FormulaC14H10N2O
-
Purity>98% (HPLC)
-
SolubilityDMSO:49 mg/mL?(220.48 mM;?Need ultrasonic)
-
SMILESO=C1Nc(cccc2)c2C1=Cc1ncccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Lozinskaya NA, et al. Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3β inhibitors. Bioorg Med Chem. 2019 May 1;27(9):1804-1817.
molnova catalog
related products
-
IM-12
IM-12 is a novel potent GSK-3β inhibitor with IC50 of 53 nM, significantly increases the β-catenin level and activates canonical Wnt signalling.
-
TWS119
A GSK-3β inhibitor with IC50 of 30 nM in a cell-free assay; can induce neurogenesis in murine ESCs.
-
Sulfaphenazole
Sulfaphenazole is an inhibitor of CYP2C9 (Ki: 0.3 μM) that demonstrates at least 100-fold selectivity over other CYP450 isoforms (Ki: 63/29 μM for CYP2C8/CYP2C18, respectively, and no activity at CYP1A1, CYP1A2, CYP3A4, CYP2C19).
